Partnerships

Sunnybrook forms new industry partnership to advance WaveCheck technology

Co-development agreement, brokered by MaRS Innovation, to advance ultrasound chemotherapy monitoring technology as clinical tool

TORONTO (March 12, 2015) — Sunnybrook Health Sciences Centre and MaRS Innovation today announced a co-development agreement for WaveCheck, an ultrasound technology that transforms conventional equipment so that physicians can monitor a breast cancer tumour’s response to chemotherapy.

This announcement was covered in Biotechnology Focus, Aunt Minnie.com (radiology blog), dotmed.com, Bio-Medicine.org, Bloomberg Business and Research Views.

The partnership with GE Healthcare, brokered by MaRS Innovation, seeks to develop WaveCheck as a clinical tool that gives clinicians rapid, improved transparency to determine if breast cancer tumors are responding to chemotherapy.

WaveCheck is a clinical technique invented, refined and tested by Dr. Gregory Czarnota, chief of Radiation Oncology at Sunnybrook’s Odette Cancer Centre, and Michael C. Kolios, professor of Physics and associate dean, Research and Graduate Studies, in Ryerson University’s Faculty of Science. Their technology uses ultrasound to visually demonstrate whether chemotherapy is destroying a breast cancer tumour at the beginning of chemotherapy treatment in as little as one week. If applied to the clinic, this knowledge has the power to transform patient experience, since existing breast cancer patients typically wait until the end of treatment, anywhere from four to six months, to know if their tumor has responded.

In early clinical testing, WaveCheck’s inexpensive, non-invasive, image-guided technology (shown here) shows promise as an accurate, efficient way to monitor tumour response. Sunnybrook has partnered with GE Healthcare to co-develop WaveCheck as a clinical tool.

In early clinical testing, WaveCheck’s inexpensive, non-invasive, image-guided technology shows promise as an accurate, efficient way to monitor tumour response, opening the door to tailored treatment.

The agreement leverages GE Healthcare’s extensive ultrasound technology and market expertise in bringing new ultrasound innovations to global hospitals and clinics with Sunnybrook’s leadership in oncology research and cancer care through the Odette Cancer Centre.

ChipCare closes oversubscribed $5 million series A financing

With lead investment from Puffin Partners, the Ontario, Canada-based company is taking lifesaving blood-testing technology to low- and middle-income countries

ChipCare device — ChipCare’s technology will provide simple-to-use, mobile, lab-quality blood testing for remote health settings. The **University of Toronto** start-up company’s first HIV-related test, targeted at linking people with HIV to appropriate treatments, is scheduled to hit the market in late 2016.

TORONTO, March 3, 2015 — ChipCare Corporation, a University of Toronto start-up company commercializing a handheld, blood-testing platform for HIV and other infectious and non-communicable diseases has closed a $5.045 million Series A financing to bring its first-generation product to market while further developing the platform’s next generation products.

The Wall Street Journal‘s Venture Capital Dispatch blog, Yonge Street Media, BetaKit and PEHub covered this announcement, along with the University of Toronto’s news site and a follow-up BetaKit article on how smartphones and start-ups are increasing access to healthcare. Information about past ChipCare investment rounds and other company information is available in our ChipCare news archive.

Insufficient access in remote health settings to simple, accurate and affordable diagnostic tests makes it difficult to provide timely, evidence-based clinical care. Current technology within central laboratories cannot fulfill the existing need in remote health settings, including community level health facilities, remote communities, emergency departments, ICUs and doctors’ offices. The result is millions of preventable deaths from infectious and non-communicable diseases globally, reduced economic growth, and limited human development.

ChipCare’s technology will provide simple-to-use, mobile, lab-quality blood testing in remote health settings. The company’s first HIV-related test, targeted at linking people with HIV to appropriate treatments, is scheduled to hit the market in late 2016. The company is developing other products that leverage unique attributes of ChipCare’s technology.

Puffin Partners, LP, of Dallas, Texas led the financing round, which includes existing investors MaRS Innovation and Maple Leaf Angels, and new investors, including the Winfield Venture Group, Epic Capital, and additional Canadian and U.S. Angel investors.

Triphase Accelerator announces new cancer collaboration with Sunnybrook Research Institute

February 27, 2015
Susanne Staer
Industry Partners

TORONTO and SAN DIEGO (Feb. 26, 2015) — Triphase Accelerator Corporation has entered into an academic center collaboration with Sunnybrook Research Institute (SRI), the research arm of Sunnybrook Health Sciences Centre, a MaRS Innovation member institution. MaRS Innovation is also a Triphase investor.

Under the agreement, SRI will assist in the development of Triphase’s novel, first-in-class, fully human bi-specific antibody TRPH 011 and evaluate the role of bifunctional targeting of VEGFR-2 and TIE 2 receptors in cancer. TRPH 011 binds and neutralizes VEGFR-2/KDR and TIE 2 receptors simultaneously, resulting in sustained inhibition of tumor growth and angiogenesis (the formation of new blood vessels from pre-existing vessels and a fundamental step in the transition of tumors from a benign to a malignant state).

Under the terms of the agreement, Triphase will provide funding to the laboratory of Dr. Robert S. Kerbel, senior scientist in the Biological Sciences Platform at SRI. Dr. Kerbel and his colleagues will evaluate TRPH 011 in preclinical pharmacology models. Triphase will use the findings to advance the TRPH 011 program toward an Investigational New Drug (IND) filing.

Life Sciences Ontario publishes first substantial benchmarking data for sector’s performance

If you work in the life sciences in Ontario, your wages are approximately 26.5 per cent higher than those of the provincial average. On the other hand, if you’re a recent science graduate, you’re facing a challenging unemployment rate of 18.9 per cent.

These are only two of the data points described in the Life Sciences Ontario (LSO) Sector Report 2015, which is the first of its kind to provide well-defined data that clearly measure and report on the sector’s benchmarking and its economic contributions. It also gives policymakers evidence-based data to benchmark Ontario’s performance, such as approximately 83,000 highly skilled workers, against other North American jurisdictions.

MaRS Innovation is a member of the LSO, which has also published an infographic summarizing the 2015 sector report’s findings. This announcement was covered in BetaKit.

“In the past, making accurate comparisons was virtually impossible due to inconsistencies in both data and methodologies,” says Jason Field, LSO’s president and CEO. “As the voice for the life sciences community, it’s our role to research and publish a report that would substantially quantify and articulate the sector’s impact. We want to help Ontario’s life sciences sector reach its full economic and social potential, which will benefit all Ontarians. Producing a sector report to establish a baseline and help inform policy decisions is a key milestone in that process.”

Some of the report’s highlights include:

Ontario’s Life Sciences generates approximately $40 billion in annual revenues.
That revenue translates to approximately $38.5 billion in total contributions to Ontario’s Gross Domestic Product (GDP).
The life sciences employ approximately 83,000 highly-skilled workers at more than 5,600 establishments in Ontario.
Ontario’s sector ranks among the top clusters in North America (top ten by employment and top three by establishments).
The sector’s job growth outpaced the provincial average by nearly 10 per cent between 2001 and 2013, showing resilience during the 2008 economic downturn.

Ontario government announces over $400,000 for eQOL’s home dialysis technology

February 19, 2015
Susanne Staer
eQOL Inc.

SAULT STE. MARIE, February 13, 2015 — eQOL, a Sault Ste. Marie-based company working to enhance patient independence and a graduate of the second University of Toronto Early-Stage Technology (UTEST) incubator’s second cohort, has received $435,475 from the Ontario Government. David Orazietti, MPP for Sault Ste. Marie, made the announcement on February 13, 2015.

This announcement was covered by BetaKit, The Sault Star and SooToday.com.

The funding, which includes $415,000 through the Northern Ontario Heritage Fund Corporation (NOHFC) and $20,475 to hire an intern under the Northern Ontario Internship Program also through NOHFC, will allow eQOL to complete clinical studies using their Dialysis Platform for Communication, Assistance and Training (DiCAT) product.

David Orazetti and Binh Nguyan — MPP David Orazetti (left) and Binh Nguyan (centre), CEO of eQOL, at the Northern Ontario Internship Program announcement on February 13, 2014. Photo courtesy of SooToday.com.

“With this support from our government, eQOL is able to use their innovative new technology in clinical studies – the first step towards commercializing the technology,” said Orazietti. “This software will not only enhance the quality of life for dialysis patients, but will also benefit our health care system and community as it streamlines processes and alleviates strain on hospital resources.”

DiCAT, a mobile technology solution for independent/home dialysis, aims to simplify and reduce the intimidation that patients experience with this self-care process. Its iPad and web-based applications provide enhanced connectivity, access to resources, and process management, which will promote a shift from in-centre care to in-home care. Successfully completing the clinical study and implementing DiCAT will allow patients who live far away from healthcare centres to receive care at home without having to relocate, which will have a great impact in northern regions.

CoursePeer and National Franchise Group partner to launch Franchise University

February 9, 2015
Susanne Staer
CoursePeer

Signarama Canada first global franchise group to rollout solution

TORONTO, January 29, 2015 — CoursePeer Inc. and National Franchise Group have partnered to launch Franchise University, a service offering global franchise groups a powerful cloud-based training and collaboration solution for their franchisees. Signarma Canada, the global sign industry leader ranked 28^th on Franchise Direct’s Top 100 Global Franchises list, is among the first brands to join.

CoursePeer, a University of Toronto and MaRS Innovation company that provides learning and collaboration solutions for enterprise and government, will begin a full rollout of Franchise University solution for Signarama in the first quarter of 2015.

“Training a new hire and retraining existing employees can be very difficult and a time-consuming task for a franchise operator. Cloud-based approved training allows staff to be trained and retrained without losing focus on the franchise’s daily operations,” said Ghassan Barazi, CEO of National Franchise Group.

CoursePeer’s platform allows organizations to design and upload advanced training curriculum for the various departments while leveraging its authoring tools. Additionally, off-the-shelf training courses are available in marketing, sales, customer service, project management, and other topics. CoursePeer was launched and incorporated through the University of Toronto Early-Stage Technology program (UTEST)’s first cohort; the company announced a partnership focused on increasing civic-engagement with municipal issues involving several Greater Toronto Area municipalities in 2014.

Funding call: MaRS Innovation Industry Access Program (MI-IAP) accepting applications to February 6

Researchers working in orphan indications, immuno-oncology, respiratory diseases, diabetes, and other key areas invited to submit a brief Statement of Interest

The commercialization process: Moving transformational ideas from the lab bench to the street — MaRS Innovation’s commercialization process helps inventors move their transformational ideas from the lab bench to the street.

The MaRS Innovation Industry Access Program (MI-IAP) is a simple, formalized process for marketing early-stage technologies to MI’s industry partners: Baxter, LifeLabs (formerly CML Healthcare), GSK, Johnson & Johnson, Pfizer and IRICoR/Merck.

The program’s goal is to secure funding for researchers within MI’s membership through these collaborative, strategic R&D partnership programs.

The program is open to any researcher affiliated with MI’s 16 member institutions working on technologies in:

Orphan indications
Immuno-oncology
Respiratory system diseases (e.g., Chronic obstructive pulmonary disease (COPD), asthma, lung cancer, etc.)
Diabetes
Neuroscience
Orthopaedics
General surgery

Successfully run in November 2013 and March 2014, the MI-IAP allows researchers to easily determine whether an industry partner is interested in co-developing their technologies. The application process is deliberately brief at the outset.

MaRS Innovation collaborating with Johnson & Johnson Innovation and Janssen to advance Cardiac, Diabetes and Depression technologies

January 12, 2015
Susanne Staer
Centre for Addiction and Mental Health (CAMH)

TORONTO, Jan. 12, 2015 — MaRS Innovation, the commercialization agent for Ontario’s 15 leading academic institutions, today announced that it has formed a research collaboration with Johnson & Johnson Innovation, LLC and its Canadian affiliate, Janssen Inc., to advance three technologies focused on cardiac, diabetes and depression, respectively.

This announcement was covered in Lab Product News.

“These three projects reflect the quality of innovation present in Toronto’s research community for our industry partners, and Toronto’s progress in addressing healthcare issues of international concern,” said Dr. Raphael Hofstein, president and CEO of MaRS Innovation. “Johnson & Johnson Innovation is a long-term strategic partner of MaRS Innovation and of our members; our collaboration reflects the benefits to accessing our members’ deal flow through MaRS Innovation. Through these deals and other scientific exchanges, we see increased interest in Toronto’s innovation and entrepreneurship community.”

The projects’ principal investigators are researchers from the University Health Network (UHN), the Centre for Addiction and Mental Health (CAMH) and the University of Toronto. This announcement follows Johnson & Johnson Innovation’s December 2013 commitment to collaborate on early-stage drug development projects.

Baycrest’s “My Virtual Dream” brain exhibit at Ontario Science Centre Jan 17-18, 2015

MaRS Innovation is a My Virtual Dream event sponsor and commercialization partner

Toronto, ON (January 12, 2015) – Baycrest Health Sciences’ dazzling brain science exhibit from 2013 Scotiabank Nuit Blanche will be on show at the Ontario Science Centre’s BRAINFest, Jan. 17-18.

My Virtual Dream is an innovative and interactive live performance experience at the intersection of science, art and music. The installation will enable participants to use their brain waves to communicate with each other through an immersive audio and visual expression that will be projected onto video screens.

“Participating at BRAINFest is a great way to share Baycrest’s renowned strengths in cognitive neuroscience in a highly artistic and interactive way with the public,” says Dr. Randy McIntosh, vice-president of Research and Director of Baycrest’s Rotman Research Institute. “Baycrest wishes to thank the Ontario Brain Institute for bringing My Virtual Dream into the Ontario Science Centre and to MaRS Innovation as our key collaborative partner.”

The concept for My Virtual Dream is inspired by an ongoing international project led by Dr. McIntosh and the Rotman to build a virtual, functional brain – a research and diagnostic tool that could one day revolutionize brain healthcare.

The installation, created by Baycrest and the University of Toronto for Nuit Blanche 2013, was a huge hit with fans of the festival. It also represented an extraordinary neuroscience experiment that explored how people can collectively synchronize their brain waves to co-create a multi-sensory environment that merges art, science and technology. In a single night, Rotman researchers collected brain data from over 500 people who signed on to be research subjects.

MaRS Innovation’s top 10 portfolio stories for 2014

December 15, 2014
Susanne Staer
Acquisitions

MaRS Innovation enjoyed an exceptional year in 2014. Our team continues to collaborate with researchers within our membership to help bridge the commercialization gap between their world-leading research and creating successful start-up companies or licenses.

Here are our picks for the top 10 news stories from MaRS Innovation’s portfolio.

1. Triphase Accelerator Corporation, in which MaRS Innovation is an investor, started the year with a bang by signing a collaboration and option agreement with Celgene Corporation. In October, Triphase initiated a Phase I clinical study to evaluate marizomib in Glioblastoma (GBM) with Celgene, signed an agreement to provide Celgene with an option to acquire a new bi-specific antibody (licensed by Triphase from PharmAbcine) and closed the year by announcing that Triphase’s proteasome inhibitor, marizomib, demonstrates potent synergistic anti-multiple myeloma activity in combination with pomalidomide.

2. Flybits Inc., spun out of Ryerson University, announced a $3.75 million Series A financing with Robert Bosch Venture Capital to advance its context-aware mobile experience platform. The company was also named a Red Herring Top 100 North America winner.

3. XLV Diagnostics Inc., spun out from Sunnybrook Health Sciences Centre and the Thunder Bay Regional Research Institute, secured a $3 million Series A investment round with Boston-based Bernard M. Gordon Unitrust. XLV’s product will provide mammography image quality equivalent to top-of-the-line mammography machines currently in use, and will do so at a fraction of the cost of current generation systems. The funding will support continued product development and regulatory approval.